Sandbox Reserved 1657
From Proteopedia
(Difference between revisions)
Line 13: | Line 13: | ||
== Disease == | == Disease == | ||
- | It is understood that the Notch receptors play an important role in cancer development in mammals. These oncogenic mechanisms of the ''Notch'' receptors are dependant on its intracelluclar signaling. Therefore, in order to understand how the cancer develops due to these receptors, it is necessary to understand the | + | It is well understood that the [https://en.wikipedia.org/wiki/Notch_proteins Notch] receptors play an important role in cancer development in mammals. These oncogenic mechanisms of the ''Notch'' receptors are dependant on its intracelluclar signaling. Therefore, in order to understand how the cancer develops due to these receptors, it is necessary to understand the [https://en.wikipedia.org/wiki/Notch_signaling_pathway Notch pathway]. |
- | + | As an example, the target genes in the pathway of [https://en.wikipedia.org/wiki/Notch_3 NOTCH3] or other subtypes of the ''Notch'' receptors are expressed by a variety of translocation, [https://en.wikipedia.org/wiki/Post-translational_modification post-translational modifications] and activation of ligands associated to it. Following translation, Furin-like convertase modifies the ''Notch'' receptor by proteolytic cleavage at site 1 (S1) and transported to the cell surface held together by the heterodimerization (HD) domain. The ''Notch'' receptor on the signal‐receiving cell binds to a ligand on the cell surface of a neighboring signal‐sending cell, causing it to get activated. This binding causes a change in the conformation of the receptor. Site 2 (S2), present within the negative regulatory region (NRR) domain, is thus exposed for cleavage by a disintegrin and metalloprotease (ADAM). Notch cleavage at S2 generates the membrane‐anchored Notch extracellular truncation (NEXT) fragment, a substrate for the γ‐secretase complex. Thus, the ''Notch'' receptor is cleaved by the γ-secretase complex. Following γ-secretase cleavage, the intracellular domain (ICD) of NOTCH3 translocates to the nucleus where it interacts with the DNA-binding factor RBPJ and co-activators of the [https://en.wikipedia.org/wiki/MAML1 mastermind-like (MAML)] family to form a transcriptional activation complex. <ref>doi:10.1634/theoncologist.2017-0677</ref> | |
- | NRR mutations act by destabilizing or completely unfolding the HD domain, relaxing the interface that protects the S2 site. These mutations associated with the HD domain in the NRR domain lead to increased Notch signaling by way increased expression of the target gene that leads to abnormal levels of the ICD of Notch. These abnormally high levels of ICD of the Notch receptors are understood to be the cause of the development of several different human cancers.<ref name="oncogene">Bernasconi-Elias, P., Hu, T., Jenkins, D. et al. Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies. Oncogene 35, 6077–6086 (2016). https://doi.org/10.1038/onc.2016.133</ref> Activating mutations of two different regions of NOTCH1 were present in >50% of T-cell acute lymphoblastic leukemia (T-ALL). Abnormally high amounts of NOTCH3 were reported to be in approximately 10–25% of ovarian adenocarcinomas. NOTCH3 mutations have also been reported in around 1% of head and neck squamous carcinomas, ovarian cancers, and lung adenocarcinoma. <ref name="oncogene" /> | + | NRR mutations act by destabilizing or completely unfolding the HD domain, relaxing the interface that protects the S2 site. These mutations associated with the HD domain in the NRR domain lead to increased Notch signaling by way increased expression of the target gene that leads to abnormal levels of the ICD of Notch. These abnormally high levels of ICD of the Notch receptors are understood to be the cause of the development of several different human cancers.<ref name="oncogene">Bernasconi-Elias, P., Hu, T., Jenkins, D. et al. Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies. Oncogene 35, 6077–6086 (2016). https://doi.org/10.1038/onc.2016.133</ref> Activating mutations of two different regions of [https://en.wikipedia.org/wiki/Notch_1 NOTCH1] were present in >50% of [https://science.sciencemag.org/content/306/5694/269 T-cell acute lymphoblastic leukemia (T-ALL)]. Abnormally high amounts of NOTCH3 were reported to be in approximately 10–25% of ovarian adenocarcinomas. NOTCH3 mutations have also been reported in around 1% of head and neck squamous carcinomas, ovarian cancers, and lung adenocarcinoma. <ref name="oncogene" /> |
+ | |||
+ | Further research on the NOTCH3 activation is key to providing a way forward to identify the different human cancers that could potentially respond to therapy based on [https://www.nature.com/articles/onc2016133#Abs1 NOTCH3-selective inhibitory antibodies].<ref name="oncogene" /> Furthermore, the development of well-characterized diagnostic reagents and biomarkers tests related to the ''Notch'' pathway is essential to fully deciphering the complex role of ''Notch'' receptors in cancer, thereby promoting more successful trials of similar ''Notch'' pathway inhibitors as a plausible treatment for cancer patients.<ref name="roles">doi:10.1146/annurev-pathol-052016-100127</ref> | ||
== Relevance == | == Relevance == | ||
- | The ''Notch'' signaling pathway regulates cell-cell interaction, embryogenesis as well as various other biological functions in adult tissues. It is a highly conserved pathway. Its relevance and clinical significance lie in the mutations in the ''Notch'' gene that have been identified in an extensive range of cancers in mammals. These mutations can change the activity of the pathway rendering it capable of causing various diseases depending on the sub-type of the ''Notch'' receptor and more importantly, causing it to play an oncogenic or tumor-suppressive role. <ref | + | The ''Notch'' signaling pathway regulates cell-cell interaction, [https://en.wikipedia.org/wiki/Embryonic_development embryogenesis] as well as various other biological functions in adult tissues. It is a highly conserved pathway. Its relevance and clinical significance lie in the mutations in the ''Notch'' gene that have been identified in an extensive range of cancers in mammals. These mutations can change the activity of the pathway rendering it capable of causing [https://pubmed.ncbi.nlm.nih.gov/22306179/ various diseases] depending on the sub-type of the ''Notch'' receptor and more importantly, causing it to play an oncogenic or tumor-suppressive role.<ref name="roles" /> |
The ''Notch'' signaling pathway has been studied comprehensively and various aspects of this pathway are very well known. Despite this, it is essential to study the pathway further, so as to understand the role it plays in cancer development and explore novel treatment strategies focusing on the ''Notch'' pathway. | The ''Notch'' signaling pathway has been studied comprehensively and various aspects of this pathway are very well known. Despite this, it is essential to study the pathway further, so as to understand the role it plays in cancer development and explore novel treatment strategies focusing on the ''Notch'' pathway. |
Revision as of 20:29, 14 January 2021
5CZX
|
References
- ↑ Guo Z, Ohlstein B. Stem cell regulation. Bidirectional Notch signaling regulates Drosophila intestinal stem cell multipotency. Science. 2015 Nov 20;350(6263). pii: 350/6263/aab0988. doi:, 10.1126/science.aab0988. PMID:26586765 doi:http://dx.doi.org/10.1126/science.aab0988
- ↑ Callahan R, Smith GH. MMTV-induced mammary tumorigenesis: gene discovery, progression to malignancy and cellular pathways. Oncogene. 2000 Feb 21;19(8):992-1001. doi: 10.1038/sj.onc.1203276. PMID:10713682 doi:http://dx.doi.org/10.1038/sj.onc.1203276
- ↑ Aburjania Z, Jang S, Whitt J, Jaskula-Stzul R, Chen H, Rose JB. The Role of Notch3 in Cancer. Oncologist. 2018 Aug;23(8):900-911. doi: 10.1634/theoncologist.2017-0677. Epub, 2018 Apr 5. PMID:29622701 doi:http://dx.doi.org/10.1634/theoncologist.2017-0677
- ↑ 4.0 4.1 4.2 Bernasconi-Elias, P., Hu, T., Jenkins, D. et al. Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies. Oncogene 35, 6077–6086 (2016). https://doi.org/10.1038/onc.2016.133
- ↑ 5.0 5.1 Aster JC, Pear WS, Blacklow SC. The Varied Roles of Notch in Cancer. Annu Rev Pathol. 2017 Jan 24;12:245-275. doi:, 10.1146/annurev-pathol-052016-100127. Epub 2016 Dec 5. PMID:27959635 doi:http://dx.doi.org/10.1146/annurev-pathol-052016-100127